scholarly journals VIRAL COINFECTIONS IN PATIENTS WITH CHRONIC HEPATITIS B: THEIR PREVALENCE AND CLINICAL SIGNIFICANCE

2020 ◽  
Vol 4 (2) ◽  
pp. 171-176
Author(s):  
D. V. Tserashkou ◽  
◽  
V. M. Mitsura ◽  
E. V. Voropaev ◽  
O. V. Osipkina ◽  
...  

Background. Hepatitis B virus (HBV) infection remains a global public health problem. Objective – to analyze the prevalence of viral coinfections with human immunodefciency virus (HIV), hepatitis C virus (HCV), hepatitis delta virus (HDV), TT-viruses and SENV in patients with chronic hepatitis B (CHB) and to assess their influence on liver disease severity. Material and methods. The observational cross-sectional study included 287 patients with chronic hepatitis B virus (HBV) – those with monoinfection and coinfected with HIV, HCV, HDV. Routine hematological and biochemical tests were performed, serum HBV DNA level as well as liver fbrosis stage were measured. Blood samples from 62 patients for Torque teno virus (TTV), Torque teno mini virus, Torque teno midi virus, SENV (D and H genotypes) DNAs were examined by polymerase chain reaction. Results. Among patients with CHB the prevalence of coinfection HBV + HIV is 6.6%, HBV + HCV – 6.3%, HBV + HDV – 3.8% and HBV + HDV + HCV – 1.7%. CHB patients coinfected with HIV, HCV, HDV had more pronounced biochemical differences and higher proportion of liver cirrhosis vs. HBV-monoinfected ones. The detection rate of TT viruses and their various combinations in patients with CHB is 91.9%, SENV – 66.1%. Conclusion. Coinfection with HIV, HCV, HDV in CHB patients is associated with more severe forms of chronic liver disease as compared to HBV-monoinfection. TT viruses and SENV are widespread and don’t affect the severity of liver disease in patients with CHB.

2013 ◽  
Vol 20 (12) ◽  
pp. 890-896 ◽  
Author(s):  
G. Y. Minuk ◽  
S. MacRury ◽  
J. Uhanova ◽  
S. Caouette ◽  
N. Coleman ◽  
...  

2006 ◽  
Vol 101 (11) ◽  
pp. 2537-2545 ◽  
Author(s):  
Mehdi Mohamadnejad ◽  
Ghodrat Montazeri ◽  
Atoosa Fazlollahi ◽  
Farhad Zamani ◽  
Jafar Nasiri ◽  
...  

2013 ◽  
Vol 34 (7) ◽  
pp. e238-e245 ◽  
Author(s):  
Simon B. Larsson ◽  
Anders Eilard ◽  
Sebastian Malmström ◽  
Charles Hannoun ◽  
Amar P. Dhillon ◽  
...  

1983 ◽  
Vol 28 (11) ◽  
pp. 962-966 ◽  
Author(s):  
Alfredo Alberti ◽  
Federico Tremolada ◽  
Giovanna Fattovich ◽  
Flavia Bortolotti ◽  
Giuseppe Realdi

1996 ◽  
Vol 41 (12) ◽  
pp. 2447-2452 ◽  
Author(s):  
Alessandra Mangia ◽  
Young-Hwa Chung ◽  
Jay H. Hoofnagle ◽  
Larry Birkenmeyer ◽  
Isa Mushahwar ◽  
...  

1991 ◽  
Vol 19 (02) ◽  
pp. 121-129 ◽  
Author(s):  
H. Tajiri ◽  
K. Kozaiwa ◽  
Y. Ozaki ◽  
K. Miki ◽  
K. Shimuzu ◽  
...  

We studied the effect of Sho-saiko-to (Xiao-Chai-Hu-Tang) on HBeAg clearance rate (SN rate) in fourteen children with chronic hepatitis B virus (HBV) infection and with sustained liver disease. Seven of fourteen patients (50.0%) became HBeAg negative in the average observation period of 0.47 years(0.2-0.9 years). Four of those seven patients developed anti-HBe. The annual SN rate in the She-saiko-to treated group was apparently higher than the natural annual SN rate (22.7%) of 22 untreated patients retrospectively reviewed from the onset of hepatitis. Sho-saiko-to seemed to promote clearance of HBeAg in children with chronic HBV infection and with sustained liver disease. Sho-saiko-to may be an useful drug for such patients.


Sign in / Sign up

Export Citation Format

Share Document